Skip to main content

Table 2 Collection rate of EQ-5D and claims data

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

 

QOL population

Cost population

 

Taxane

S-1

Taxane

S-1

 

N = 175

N = 208

N = 70

N = 76

Baseline/Month 1

175/175 (100)

208/208 (100)

54

66

Month 3

151/171 (88.3)

168/201 (83.6)

70

70

Month 6

138/168 (82.1)

146/190 (76.8)

66

66

Month 12

107/149 (71.8)

132/170 (77.6)

49

56

Month 18

75/126 (59.5)

107/158 (67.7)

41

45

Month 24

68/117 (58.1)

93/137 (67.9)

38

45

Month 30

51/101 (50.5)

68/110 (61.8)

33

35

Month 36

45/90 (50.0)

47/84 (56.0)

32

27

Month 42

27/61 (44.3)

31/61 (50.8)

29

14

Month 48

18/39 (46.2)

21/37 (56.8)

18

15